Showing 1261-1270 of 7536 results for "".
DermWireTV: Soliton's Resonic Launch, Natroba for Scabies, UV Safety
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-solitons-resonic-launch-natroba-for-scabies-uv-safety/19938/Skin Cancer awareness month provides an opportunity for dermatologists to double down on patient outreach as the AAD launches the “Skin Cancer, Take a Hike” steps challenge. Soliton’s Rapid Acoustic Pulse Device launches under the name Resonic. Natroba (Spinosad) Topical Suspension from ParaPRO is nRecognizing and Treating Psoriasis in Skin of Color
https://practicaldermatology.com/columns/clinical-focus-1/recognizing-and-treating-psoriasis-in-skin-of-color/23493/Psoriasis may be more common across skin types than once believed.DermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketOut With the Old, In With the New
https://practicaldermatology.com/topics/psoriasis/out-with-the-old-in-with-the-new-1/23430/A “new” way of assessing psoriasis severity may improve access to care.DERM2020 Content Recap: Kara Gooding, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-kara-gooding-pa-c/19841/DERM2020 Faculty Kara Gooding, PA-C talks a bit about the case she presented at DERM2020.Continuity of Psoriasis Care in the Era of COVID-19
https://practicaldermatology.com/columns/clinical-focus-1/continuity-of-psoriasis-care-in-the-era-of-covid-19/23285/While there’s no data about susceptibility to COVID-19 in psoriasis, there is relevant information on infectious complications from biologics.COVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, aInjectable Beauty: New Uses for Dermal Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/injectable-beauty-new-uses-for-dermal-fillers/19766/Today fillers are being used to do more than just chase wrinkles and folds, shares Jeanette Black, MD. Some exciting new uses include biostimulation with Sculptra or hyperdilute Radiesse to addresscellulite and skin laxity along with the use of intradermal hyaluronic acid-based fillers for skin hydrExploring Interactions Between the Pharmaceutical Industry and Dermatology Offices
https://practicaldermatology.com/topics/practice-management/exploring-interactions-between-the-pharmaceutical-industry-and-dermatology-offices/23239/There can be benefits to interaction with industry, but it’s essential to be aware of potential pitfalls.Setting Compensation Expectations for Non-Surgical Providers
https://practicaldermatology.com/topics/practice-management/setting-compensation-expectations-for-non-surgical-providers/23227/It’s important that all parties understand the actual costs associated with a position in order to set realistic revenue goals.